Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01003990 · ClinicalTrials.gov registry record · Phase 3
Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 710
- Enrollment target
NCT01003990 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 710 participants.
The verdict
NCT01003990, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 710 participants
- Enrollment target
Study Summary
The purpose of this study is to provide atazanavir or tenofovir-emtricitabine to HIV-infected subjects who have completed atazanavir or tenofovir-emtricitabine therapy on a previous BMS sponsored clinical trial and to collect long-term safety information on the treated population.
Interventions
- DRUG Atazanavir
- DRUG Tenofovir/Emtricitabine
- DRUG Lopinavir/ritonavir
- DRUG Atazanavir/Ritonavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 710 participants |
| Start Date | 2002-10 |
| Est. Completion | 2016-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01003990
The ClinicalTrials.gov registry entry for NCT01003990 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 710 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Atazanavir is the first listed.
NCT01003990 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01003990 about?
NCT01003990 is a clinical study titled "Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access". The purpose of this study is to provide atazanavir or tenofovir-emtricitabine to HIV-infected subjects who have completed atazanavir or tenofovir-emtricitabine therapy on a previous BMS sponsored clinical trial and to collect long-term safety information on the treated population.
What is the current status of trial NCT01003990?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 710 participants. The study started on 2002-10. Estimated completion is 2016-02.
What interventions are being tested in trial NCT01003990?
The interventions under investigation include: Atazanavir (DRUG), Tenofovir/Emtricitabine (DRUG), Lopinavir/ritonavir (DRUG), Atazanavir/Ritonavir (DRUG).
Who is sponsoring clinical trial NCT01003990?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.